Komipharm International Past Earnings Performance
Past criteria checks 0/6
Komipharm International has been growing earnings at an average annual rate of 27.1%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
27.1%
Earnings growth rate
27.6%
EPS growth rate
Pharmaceuticals Industry Growth | 11.3% |
Revenue growth rate | 3.7% |
Return on equity | -9.8% |
Net Margin | -9.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Komipharm International (KOSDAQ:041960) A Risky Investment?
Mar 27A Look At Komipharm International's (KOSDAQ:041960) Share Price Returns
Feb 26Is Komipharm International Co., Ltd.'s (KOSDAQ:041960) Shareholder Ownership Skewed Towards Insiders?
Jan 22Komipharm International (KOSDAQ:041960) Is Carrying A Fair Bit Of Debt
Dec 18Revenue & Expenses BreakdownBeta
How Komipharm International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 42,647 | -3,979 | 10,937 | 5,945 |
30 Sep 23 | 41,478 | -9,507 | 10,609 | 5,355 |
30 Jun 23 | 41,736 | -9,075 | 10,478 | 5,548 |
31 Mar 23 | 39,917 | -7,242 | 10,172 | 3,655 |
31 Dec 22 | 39,801 | -6,514 | 10,420 | 2,536 |
30 Sep 22 | 39,803 | -2,083 | 10,010 | 3,688 |
30 Jun 22 | 38,405 | -3,540 | 10,029 | 4,353 |
31 Mar 22 | 36,353 | -5,516 | 9,714 | 4,650 |
31 Dec 21 | 35,847 | -4,459 | 9,402 | 5,117 |
30 Sep 21 | 35,632 | -4,293 | 9,579 | 4,760 |
30 Jun 21 | 36,223 | -2,829 | 9,755 | 3,382 |
31 Mar 21 | 37,610 | -1,006 | 9,994 | 3,658 |
31 Dec 20 | 37,160 | -2,816 | 10,188 | 3,266 |
30 Sep 20 | 37,675 | -21,363 | 10,221 | 5,806 |
30 Jun 20 | 37,907 | -21,040 | 10,111 | 6,286 |
31 Mar 20 | 36,423 | -22,231 | 10,279 | 4,828 |
31 Dec 19 | 35,490 | -21,363 | 10,097 | 4,649 |
30 Sep 19 | 34,108 | -12,369 | 11,531 | 1,286 |
30 Jun 19 | 34,315 | -12,756 | 11,263 | 1,810 |
31 Mar 19 | 35,406 | -12,898 | 10,869 | 2,911 |
31 Dec 18 | 34,994 | -14,303 | 11,067 | 2,756 |
30 Sep 18 | 35,202 | -7,916 | 9,693 | 2,193 |
30 Jun 18 | 35,721 | -6,775 | 10,028 | 1,157 |
31 Mar 18 | 34,805 | -6,412 | 10,003 | 197 |
31 Dec 17 | 36,641 | -5,096 | 9,651 | 41 |
30 Sep 17 | 37,917 | 4 | 9,226 | 124 |
30 Jun 17 | 37,387 | -854 | 8,429 | 147 |
31 Mar 17 | 38,041 | -497 | 8,300 | 162 |
31 Dec 16 | 37,636 | 289 | 8,177 | 152 |
30 Sep 16 | 38,720 | -3,474 | 8,638 | 70 |
30 Jun 16 | 38,181 | -5,460 | 9,404 | 47 |
31 Mar 16 | 37,153 | -5,044 | 9,539 | 42 |
31 Dec 15 | 36,405 | -6,548 | 9,556 | 51 |
30 Sep 15 | 35,482 | -4,839 | 9,790 | 74 |
30 Jun 15 | 36,040 | -2,027 | 9,684 | 74 |
31 Mar 15 | 34,688 | -3,071 | 9,828 | 88 |
31 Dec 14 | 34,454 | -2,150 | 9,625 | 118 |
30 Sep 14 | 31,850 | 360 | 8,769 | 106 |
30 Jun 14 | 30,693 | -244 | 8,392 | 106 |
31 Mar 14 | 28,905 | -910 | 7,890 | 135 |
31 Dec 13 | 26,465 | -82 | 7,571 | 149 |
30 Sep 13 | 24,403 | -293 | 7,371 | 188 |
30 Jun 13 | 22,645 | 629 | 6,990 | 188 |
Quality Earnings: A041960 is currently unprofitable.
Growing Profit Margin: A041960 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A041960 is unprofitable, but has reduced losses over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare A041960's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A041960 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (34.6%).
Return on Equity
High ROE: A041960 has a negative Return on Equity (-9.85%), as it is currently unprofitable.